I trained my replacement workers (yes plural) as follows: manager asked for an outline of topics, gave them three pages. They wanted to record the training, okay I'll only do one session a day because I need prep time. Instead of them letting me go at the end of the month it took an extra three months to finish. We recorded a hundred plus hours of video. There's been two sets of turnover already. It's a year since I finished and according to an insider still there, not one feature checked into source control. We were doing 30 points of features every two weeks when I was there. I offered to implement the system at a major plant to save them 1.5 million a year (their numbers) at one of the plants still using paper. Nope, the Indian team will do it. That's an MBA in charge with deep ties to all these out sourcing companies. Makes me ill.
The guys that replaced me from India haven't committed a single worthwhile feature since I left eight months ago. Guess svn is racist, they should have used git.
I wish I had kept copies of the 100 hours of screen recordings. Truly Oscar winning stuff, had my co-workers in tears the crap I was going on about. The perils of not running unit tests and so on. Good luck finding anything useful in that 100 hours.
I was asked to train my replacement from India about one year ago. I gave my manager a list of everything they needed to know. They wanted me to do sessions to train them. I said fine, I need prep time for each session and I'm only doing one a day. They screen recorded each session and it took about a hundred hours over three months. I buried them in minutia. If anyone wants to go through it or search it there's a hundred hours of tedious monotone instruction. It's been eight months since I left, no significant features committed to source control. We were doing major releases every month previously. They are thinking of bringing us back now but it is too late we've all moved on to better work. Company is losing millions a year by not having all of their refineries using this custom system that's been eight years in development. Tens of millions to re write from scratch.
I've heard they are considering bringing us back but we have all moved on to better things now.
Reovirus enhances radiation cytotoxicity in vitro and in vivo
A Phase I study of a wild-type reovirus (Reolysin) given intravenously to patients with advanced malignancies
Reovirus salvage of squamous cell cancer-contaminated wounds
Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer of immunocompetent models
Process Design and Scale-Up of New Vaccine Concepts for Biodefense
Process Development of a Scaleable Purification Protocol for the Production of Reolysin, an Oncolytic, Reovirus-Based Therapeutic
Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts
Individualized quality of life, standardized quality of life, and distress in patients undergoing a phase I trial of the novel therapeutic Reolysin (reovirus)
A Novel Intravesical Therapy for Superficial Bladder Cancer in an Orthotopic Model: Oncolytic Reovirus Therapy
The oncolytic reovirus, Reolysin, augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT 116
Reovirus Prolongs Survival and Reduces the Frequency of Spinal and Leptomeningeal Metastases from Medulloblastoma
Selective reovirus killing of bladder cancer in a co-culture spheroid model
Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation
Oncolytic Viral Therapy for Human Pancreatic Cancer Cells by Reovirus.
Systemic Reovirus Therapy of Metastatic Cancer in Immune-competent Mice
Reovirus therapy of lymphoid malignancies
AACR Annual Meeting Abstracts - The search word for the abstracts is "reovirus".
ASCO Annual Meeting Abstracts - The search word for the abstracts is "reovirus".
Reovirus as an oncolytic agent against experimental human malignant gliomas
A phase I clinical trial evaluating intralesional REOLYSIN (Reovirus) in histologically confirmed malignancies
Reovirus Induces Apoptosis in Breast and Prostate Cell Lines and Activates Nf-kB in the Nucleus: Implications for a Prognostic Factor in successful Reovirus Therapy
In Vitro and in Vivo Response of Malignant Non-Hodgkin's Lymphomas To Reovirus
Efficacy and Safety Evaluation of Human Reovirus Type 3 in a Immunocompetent Racine Glioma Model
Reovirus Prolongs Survival In Intracerebral Models Of Gliomas
Evaluation Of Reovirus Therapy For Spontaneously Occurring Canine Tumours
The Journal of Clinical Investigation - "Reovirus as a novel oncolytic agent"
Novel Viral Oncolytic Therapy Of Superficial Bladder Cancer In An Animal Model: A Comparative Study To BCG.
Reovirus Therapy of Metastatic Cancer Models in Immune-Competent Mice
Oncolytics has been granted 13 U.S. patents, three Canadian patents and two European patents covering REOLYSIN® technology and modified herpes and adenoviruses.
Date of Issue: Oct. 18, 2005
Patent Number: Canadian Patent #2,283,280
Title: Reovirus for the treatment of neoplasia.
General Description: Claims describe the use of a reovirus for the manufacture of a medicament to treat Ras-mediated neoplasia as well as methods of treating various cancers by the administration of the reovirus.
Date of Issue: Sept. 27, 2005
Patent Number: Canadian Patent #2,428,206
Title: Methods for the treatment of cellular proliferative disorders.
General Description: Claims describe methods of treating various types of cellular proliferative disorders including neurofibromatosis and neoplasms (cancers) by the administration of various strains of the reovirus.
Date of Issue: Jul.12, 2005
Patent Number: Canadian Patent #2,374,388
Title: The use of ribozymes in the detection of adventitious agents.
General Description: Covers a method of validating the purity of microbial preparations during manufacturing by detecting adventitious or contaminating viruses using a ribozyme-based assay specific for the microorganism being manufactured.
Date of Issue: Jul.18, 2005
Patent Number: European Patent #1,309,672
Title: Method of Producing Infectious Reovirus.
General Description: Covers a method of producing infectious mammalian reovirus which is suitable for clinical administration to mammals including humans.
Date of Issue: Nov.2, 2004
Patent Number: U.S. Patent #6,811,775
Title: Reovirus for the Treatment of Cellular Proliferative Disorders.
General Description: Covers using recombinant reovirus for the treatment of neoplasia and non-cancer cellular proliferative diseases such as neurofibromatosis.
Date of Issue: Oct.26, 2004
Patent Number: U.S. Patent #6,808,916
Title: Method of Extracting Virus From Cell Culture.
General Description: Covers various methods of production and processing of the reovirus.
Date of Issue: Mar.9, 2004
Patent Number: U.S. Patent #6,703,232
Title: Method of Producing Reovirus.
General Description: Covers producing reassorted reoviruses for the treatment of Ras-mediated tumours.
Date of Issue: Nov 18, 2003
Patent Number: U.S. Patent #6,649,157
Title: Viruses for the Treatment of Cellular Proliferative Disorders.
General Description: Covers treatment of Ras-mediated tumours using modified herpes viruses.
Date of Issue: Jul 22, 2003
Patent Number: U.S. Patent #6,596,268
Title: Viruses for the Treatment of Cellular Proliferative Disorders.
General Description: Covers treatment of Ras-mediated tumours using modified adenoviruses
Date of Issue: Jun 10, 2003
Patent Number: U.S. Patent #6,576,234
Title: Reovirus for the Treatment of Neoplasia.
General Description: Covers the use of combinations of reovirus strains for the treatment of Ras-mediated tumours.
Date of Issue: May 20, 2003
Patent Number: U.S. Patent #6,565,831
Title: Method of Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders.
General Description: Covers co-administration of the virus with immune-suppressing agents such as Cyclosporin.
Date of Issue: Mar 4, 2003
Patent Number: U.S. Patent #6,528,305
Title: Method of Producing Infectious Reovirus.
General Description: Covers a method of producing infectious mammalian reovirus
Date of Issue: Sep 24, 2002
Patent Number: U.S. Patent #6,455,038
Title: Reoviruses for the Treatment of Cellular Proliferative Disorders.
General Description: Covers use of various strains and combinations of reoviruses, wherein one of more of the reoviruses may be immunoprotected, as a treatment for Ras-mediated proliferative disorders such as neurofibromatosis and cancer in an immunocompetent mammal.
Date of Issue: Mar 6, 2002
Patent Number: European Patent #1,003,524
Title: Use of Reovirus as a Treatment for Ras-Mediated Neoplasms (cancers), including the use of different strains of the reovirus, various methods and administration and the treatment of various types of cancer.
Date of Issue:
Dig into the scientific articles and abstracts behind this. Look at the before and after pictures of tumours that have dissapeared. Sure I tried to get some help writing the article. What the hell is wrong with that? The internet facillitates open discussion.
Of course it sounds like spam when someone talks about new potential cancer therapies. Are we at the point where every thing should immediately be dismissed if it has the words cancer in it? Thomas Kuhn comes to mind here.
I bet the editors actually followed the links and even though the initial post was an admittedly obvious attempt to promote the story, they found it compelling enough to post. This is real, spend some time reading up and tell me that you're not just a little encouraged by the potential of this.
"i'm not sure whether it's true that all human cells have the viral response that is efficient enough for total viral clearance." The virus only replicates in cancer cells that have activated RAS. It doesn't replicate in normal cells. The Marsden study is showing that the viral clerance with intravenous administration takes about 48 hours if I remember correctly.
"also, reolysin targets the ras pathway....while ras is often either constitutively active, or overexpressed in cancer cells, it is unfortunately not the only gene which is upregulated. many other genes are often overexpressed. these genes are called oncogenes (or tumor promoting genes). there are several other genes that are often overepressed, which are separate from the ras pathway. furthermore, there are another class of genes called tumor suppressor genes, which are often inhibited or permanently lost from cancer cells. unfortunately, stopping the ras pathway will not stop cancer cells which are driven by these phenomena." The kind of RAS activation that the Reovirus exploits is implicated in probably over 2/3's of all cancers. When you talk about metatastic cancer, the kind that kills, researchers from Yale have implicated RAS.
Yes I did try to get help writing the blurb and posting it to a wider audience. Its a story that deserves to be told. I've been holding this stock for quite a number of years now and am not selling it soon. Follow the links I've posted, there is a lot of third party independent research that validates this.
1. What is a virus? A virus is a submicroscopic organism that can multiply only inside living host cells. It has a non-cellular structure lacking any intrinsic metabolism and usually comprising DNA or RNA molecules inside a protein coat. While the better known viruses are pathogenic (meaning they cause disease) many do not.
2. How do viruses behave? Viruses need to infect living cells to multiply. They typically invade a cell, then take over the cell's manufacturing capabilities so that they may replicate. Replicated viral particles then invade surrounding cells.
3. What is the reovirus? Reovirus is an acronym for Respiratory Enteric Orphan Virus. The reovirus is a naturally occurring virus to which most of us have been exposed in our lifetime. It is a non-pathogenic virus, meaning that it is not usually associated with any illness. Between 70 and 100 per cent of the population show signs of previous reovirus infection, which is usually confined to the respiratory or gastrointestinal systems in the body.
4. Where does the reovirus come from? Reovirus is found naturally in shallow pools of water, lakes or streams or in the sewage system.
5. How were its cancer-killing properties discovered? The reovirus was identified almost half a century ago, but was found to be a fairly benign virus. Because of its safety profile, it has been used for decades by scientists interested in studying how viruses infect human cells. Through the 1990s, graduate students and professors working at the University of Calgary discovered through a series of experiments that the reovirus appeared to have an ability to infect and kill many types of cancer cells, without affecting normal, healthy cells.
6. Why doesn't the reovirus infect normal cells? It enters normal cells, but when this happens, an anti-viral response mechanism is turned on and the virus is quickly eliminated. Anyone injected with reovirus is usually able to clear it completely from the body in about two weeks.
7. Why does the reovirus kill cancer cells? Scientific studies have demonstrated that approximately two-thirds of all human cancer cells have an activated Ras pathway, one of the most common set of mutations leading to cancer. An activated Ras pathway leads to a constant barrage of growth signals to the cell, causing uncontrolled growth. In cells with an activated Ras pathway, the anti-viral response appears to be turned off. When reovirus infects one of these cancer cells, it is able to replicate and eventually kill the cancer cell. Up to 5,000 progeny virus particles can then infect and kill surrounding cancer cells. Theoretically, the cycle of infection, replication and cell death will continue until there are no longer any Ras-activated cancer cells accessible.
8. How is reovirus administered to patients? Oncolytics is pursuing a three-pronged approach to developing REOLYSIN®: localized administration using REOLYSIN® as a monotherapy; systemic administration using REOLYSIN® as a monotherapy; and, combination therapy using REOLYSIN® with radiation or chemotherapy.
9. Why isn't REOLYSIN® available to people yet? Experimental drugs are not usually available to people outside clinical trials, except in rare cases. REOLYSIN® must be approved for sale by the regulatory agencies before it is made widely available to people.
10. Is REOLYSIN® available through programs such as Canada's Special Access Program? The Company will not approve requests for treatment with REOLYSIN® through programs such as the SAP. Oncolytics treats only those patients who qualify for enrollment in its clinical trials.
11. How long does the clinical trial process take? It varies, depending on the numbers of patients required for the trials and the kinds of results that are observed.
12. Why are your patient populations relatively small? The trials that have been completed, and those that are underway, are designed to show that REOLYSIN® is safe and
The body's immune response is a big question that this Marsden intravenous trial is trying to answer. It seems like the reovirus can overcome the immune response long enough to do its work. The higher doses they plan to administer will also help. Immunosuppressants can ultimately be administered too. In animal models, this approach has shown increased effectiveness too.
Take a look at the third party research links that has confirmed the company pr you mention.
This is real, its safe, and it is easy to produce.
Cheers.
Yeah I got some feedback from yahoo and stockhouse message boards before I submitted the summary to slashdot. I've done a lot of DD on this and am not selling my shares for at least a couple of years. Six bucks is way too cheap for an effective treatment for Cancer, even in American dollars...
They are planning systemic studies which means that it will be injected directly into your veins and go to where your blood goes. Only place that won't be treatable is brain cancer where direct injection will be necessary.
Its actually NOT an engineered virus. You are correct in saying that Adenovirus is genitically engineered as are most other virus oncology programs but the Reovirus is not genetically altered.
It is quite significant in terms of being able to produce large quantities of this and also in terms of safety, the Reovirus is stable and won't mutate into something dangerous.
You need to do more research. The SciAm article mentioned reovirus but it was the only one of those five treatments that wasn't engineered.
Lead Product
REOLYSIN - A potential cancer therapeutic based on the naturally occurring reovirus. REO is an acronym for respiratory enteric orphan. Orphan due to the fact that there is no known disease caused by the reovirus. 70-100% of all adult populations have been infected with the reovirus without knowing it. The oncolytic properties of the reovirus were discovered in 1998 by Dr. Patrick Lee at the University of Calgary.
Preclinical
Glioblastoma:
- glioma tumours U251N and U87lacZ implanted intracerebrally in mice
- median survival of untreated mice, 42 and 48 days
- 67% and 82% of treated animals still alive at conclusion of experiment at day 90
- complete tumour regression found in 20 of 23 of animals treated with live virus
- also tested on established glioma cell lines and surgical specimens
- widespread cell killing seen in 19 of 24 cell lines
- all primary surgical glioma specimens (9 of 9) were infected and killed
- human glioma tumour cells killed within 48 hour period (both cell lines and ex vivo glioma specimens)
- dramatic survival benefits for nude mice following intracerebral inoculation
- caused tumour regression in the presence of pre-existing anti-reovirus antibodies in immunocompetent Fischer rats
- killed tumour remote from the site of administration in immunocompetent host
- proceeding to clinical trial in patients with malignant gliomas
Medulloblastoma:
- majority of cell lines (7 of 11) were susceptible to reovirus oncolysis
- in all MB cell lines tested, Ras activity was shown to correlate with susceptibility to reovirus infection
- median survival of live virus-treated mice was 160 days, compared to 70 days control
- these data suggest that reovirus may be a novel and potentially effective therapeutic against human medulloblastoma
Breast:
- widespread cell killing was seen in all five established breast cancer cell lines and in one surgical specimen
- no cell killing observed in two cell lines established from normal breast tissue
- in mammary fat pad of SCID/NOD mice, a single injection of reovirus caused a continuous regression of the tumour during a thirty-day observation period
- independent tumours established in both flanks of the mice, a single injection of the reovirus into only one tumour resulted in complete regression of both the injected and non-injected tumours over thirty-two days
Colon:
- efficiently infected 5/5 human colon cancer cell lines (Caco-2, DLD-1, HCT-116, HT-29, and SW48)
- did not infect normal colon cell line (CCD-18Co)
- in mice model with tumour implanted in hind flank, both intratumoural and i.v. administration of reovirus resulted in significant regression
Ovarian:
- efficiently infected 4/4 human ovarian cancer cell lines (MDAH2774, PA-1, SKOV3, and SW626)
- did not infect normal ovarian cell line (NOV-31)
- in mice model with tumour implanted in hind flank, both intratumoural and i.v. administration of reovirus resulted in significant regression
- significantly greater survival benefits for reovirus treated mice
- reovirus infected ex vivo primary human ovarian surgical samples
Non-Hodgkin's Lymphomas:
- cell lines sensitive to reovirus: Raji, NC-37, UJ937 and CA46
- cell lines unaffected by reovirus: Daudi, ST486, Ramos, and A20
- ex vivo samples responded in similar ratio
- reovirus caused significant regression of in vivo Raji tumour
- reovirus may be effectivce against some types of human NHL
Prostate:
- prostate cell lines (PC-3, Ln-CaP, DU-145) were infected with reovirus
- cells were harvested at 0, 24, 48, 72, 96 and 168h post infection
- virus treatment caused significant disruption of cells as early as 24h
- the observed cytopathic/apoptotic effects of reovirus were not evident in controls
Pancreatic:
- from Matt Coffey's thesis, pancreatic cell lines Capan-1, MIAPaCa-2, PANC-1, AsPC-1, and Hs766T were infectible while BxPC-3 was not (it is known to have wild type Ras) the others have mutations in codon 12 so are expected to be infectible
Lewis lung:
- in a Lewis lung carcinoma mouse model, they [Dr. Lee, et al] demonstrated that IV treatm
No, this is a naturally occuring virus. Its not one that is genetically engineered.
The advantages are huge - easier to mass produce and much safer, it won't revert into something harmful
Slashdot Mirror
Good luck getting a decent fair price when they know everything about you.
Will Warren even be alive in five years?
Can anyone remember an add they saw on a page this week? What about one they clicked on? Ask your friends this. Most won't be able to.
I trained my replacement workers (yes plural) as follows: manager asked for an outline of topics, gave them three pages. They wanted to record the training, okay I'll only do one session a day because I need prep time. Instead of them letting me go at the end of the month it took an extra three months to finish. We recorded a hundred plus hours of video. There's been two sets of turnover already. It's a year since I finished and according to an insider still there, not one feature checked into source control. We were doing 30 points of features every two weeks when I was there. I offered to implement the system at a major plant to save them 1.5 million a year (their numbers) at one of the plants still using paper. Nope, the Indian team will do it. That's an MBA in charge with deep ties to all these out sourcing companies. Makes me ill.
The guys that replaced me from India haven't committed a single worthwhile feature since I left eight months ago. Guess svn is racist, they should have used git.
I wish I had kept copies of the 100 hours of screen recordings. Truly Oscar winning stuff, had my co-workers in tears the crap I was going on about. The perils of not running unit tests and so on. Good luck finding anything useful in that 100 hours.
I said f-it and went north to go treeplanting. Wrote an article about it here: http://www.tree-planter.com/20...
I was asked to train my replacement from India about one year ago. I gave my manager a list of everything they needed to know. They wanted me to do sessions to train them. I said fine, I need prep time for each session and I'm only doing one a day. They screen recorded each session and it took about a hundred hours over three months. I buried them in minutia. If anyone wants to go through it or search it there's a hundred hours of tedious monotone instruction. It's been eight months since I left, no significant features committed to source control. We were doing major releases every month previously. They are thinking of bringing us back now but it is too late we've all moved on to better work. Company is losing millions a year by not having all of their refineries using this custom system that's been eight years in development. Tens of millions to re write from scratch. I've heard they are considering bringing us back but we have all moved on to better things now.
I first posted this 13 years ago. Sad how long it takes http://m.slashdot.org/story/40...
Here's a small sample of papers to read. You can get the fully linked versions from the company's website:r =t.onc&message=fourth
http://www.integratir.com/custommessage.asp?ticke
Reovirus enhances radiation cytotoxicity in vitro and in vivo
A Phase I study of a wild-type reovirus (Reolysin) given intravenously to patients with advanced malignancies
Reovirus salvage of squamous cell cancer-contaminated wounds
Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer of immunocompetent models
Process Design and Scale-Up of New Vaccine Concepts for Biodefense
Process Development of a Scaleable Purification Protocol for the Production of Reolysin, an Oncolytic, Reovirus-Based Therapeutic
Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts
Individualized quality of life, standardized quality of life, and distress in patients undergoing a phase I trial of the novel therapeutic Reolysin (reovirus)
A Novel Intravesical Therapy for Superficial Bladder Cancer in an Orthotopic Model: Oncolytic Reovirus Therapy
The oncolytic reovirus, Reolysin, augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT 116
Reovirus Prolongs Survival and Reduces the Frequency of Spinal and Leptomeningeal Metastases from Medulloblastoma
Selective reovirus killing of bladder cancer in a co-culture spheroid model
Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation
Oncolytic Viral Therapy for Human Pancreatic Cancer Cells by Reovirus.
Systemic Reovirus Therapy of Metastatic Cancer in Immune-competent Mice
Reovirus therapy of lymphoid malignancies
AACR Annual Meeting Abstracts - The search word for the abstracts is "reovirus".
ASCO Annual Meeting Abstracts - The search word for the abstracts is "reovirus".
Reovirus as an oncolytic agent against experimental human malignant gliomas
A phase I clinical trial evaluating intralesional REOLYSIN (Reovirus) in histologically confirmed malignancies
Reovirus Induces Apoptosis in Breast and Prostate Cell Lines and Activates Nf-kB in the Nucleus: Implications for a Prognostic Factor in successful Reovirus Therapy
In Vitro and in Vivo Response of Malignant Non-Hodgkin's Lymphomas To Reovirus
Efficacy and Safety Evaluation of Human Reovirus Type 3 in a Immunocompetent Racine Glioma Model
Reovirus Prolongs Survival In Intracerebral Models Of Gliomas
Evaluation Of Reovirus Therapy For Spontaneously Occurring Canine Tumours
The Journal of Clinical Investigation - "Reovirus as a novel oncolytic agent"
Novel Viral Oncolytic Therapy Of Superficial Bladder Cancer In An Animal Model: A Comparative Study To BCG.
Reovirus Therapy of Metastatic Cancer Models in Immune-Competent Mice
Oncolytics has been granted 13 U.S. patents, three Canadian patents and two European patents covering REOLYSIN® technology and modified herpes and adenoviruses. Date of Issue: Oct. 18, 2005 Patent Number: Canadian Patent #2,283,280 Title: Reovirus for the treatment of neoplasia. General Description: Claims describe the use of a reovirus for the manufacture of a medicament to treat Ras-mediated neoplasia as well as methods of treating various cancers by the administration of the reovirus. Date of Issue: Sept. 27, 2005 Patent Number: Canadian Patent #2,428,206 Title: Methods for the treatment of cellular proliferative disorders. General Description: Claims describe methods of treating various types of cellular proliferative disorders including neurofibromatosis and neoplasms (cancers) by the administration of various strains of the reovirus. Date of Issue: Jul.12, 2005 Patent Number: Canadian Patent #2,374,388 Title: The use of ribozymes in the detection of adventitious agents. General Description: Covers a method of validating the purity of microbial preparations during manufacturing by detecting adventitious or contaminating viruses using a ribozyme-based assay specific for the microorganism being manufactured. Date of Issue: Jul.18, 2005 Patent Number: European Patent #1,309,672 Title: Method of Producing Infectious Reovirus. General Description: Covers a method of producing infectious mammalian reovirus which is suitable for clinical administration to mammals including humans. Date of Issue: Nov.2, 2004 Patent Number: U.S. Patent #6,811,775 Title: Reovirus for the Treatment of Cellular Proliferative Disorders. General Description: Covers using recombinant reovirus for the treatment of neoplasia and non-cancer cellular proliferative diseases such as neurofibromatosis. Date of Issue: Oct.26, 2004 Patent Number: U.S. Patent #6,808,916 Title: Method of Extracting Virus From Cell Culture. General Description: Covers various methods of production and processing of the reovirus. Date of Issue: Mar.9, 2004 Patent Number: U.S. Patent #6,703,232 Title: Method of Producing Reovirus. General Description: Covers producing reassorted reoviruses for the treatment of Ras-mediated tumours. Date of Issue: Nov 18, 2003 Patent Number: U.S. Patent #6,649,157 Title: Viruses for the Treatment of Cellular Proliferative Disorders. General Description: Covers treatment of Ras-mediated tumours using modified herpes viruses. Date of Issue: Jul 22, 2003 Patent Number: U.S. Patent #6,596,268 Title: Viruses for the Treatment of Cellular Proliferative Disorders. General Description: Covers treatment of Ras-mediated tumours using modified adenoviruses Date of Issue: Jun 10, 2003 Patent Number: U.S. Patent #6,576,234 Title: Reovirus for the Treatment of Neoplasia. General Description: Covers the use of combinations of reovirus strains for the treatment of Ras-mediated tumours. Date of Issue: May 20, 2003 Patent Number: U.S. Patent #6,565,831 Title: Method of Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders. General Description: Covers co-administration of the virus with immune-suppressing agents such as Cyclosporin. Date of Issue: Mar 4, 2003 Patent Number: U.S. Patent #6,528,305 Title: Method of Producing Infectious Reovirus. General Description: Covers a method of producing infectious mammalian reovirus Date of Issue: Sep 24, 2002 Patent Number: U.S. Patent #6,455,038 Title: Reoviruses for the Treatment of Cellular Proliferative Disorders. General Description: Covers use of various strains and combinations of reoviruses, wherein one of more of the reoviruses may be immunoprotected, as a treatment for Ras-mediated proliferative disorders such as neurofibromatosis and cancer in an immunocompetent mammal. Date of Issue: Mar 6, 2002 Patent Number: European Patent #1,003,524 Title: Use of Reovirus as a Treatment for Ras-Mediated Neoplasms (cancers), including the use of different strains of the reovirus, various methods and administration and the treatment of various types of cancer. Date of Issue:
Dig into the scientific articles and abstracts behind this. Look at the before and after pictures of tumours that have dissapeared. Sure I tried to get some help writing the article. What the hell is wrong with that? The internet facillitates open discussion. Of course it sounds like spam when someone talks about new potential cancer therapies. Are we at the point where every thing should immediately be dismissed if it has the words cancer in it? Thomas Kuhn comes to mind here. I bet the editors actually followed the links and even though the initial post was an admittedly obvious attempt to promote the story, they found it compelling enough to post. This is real, spend some time reading up and tell me that you're not just a little encouraged by the potential of this.
"i'm not sure whether it's true that all human cells have the viral response that is efficient enough for total viral clearance."
d ings.html
The virus only replicates in cancer cells that have activated RAS. It doesn't replicate in normal cells. The Marsden study is showing that the viral clerance with intravenous administration takes about 48 hours if I remember correctly.
"also, reolysin targets the ras pathway....while ras is often either constitutively active, or overexpressed in cancer cells, it is unfortunately not the only gene which is upregulated. many other genes are often overexpressed. these genes are called oncogenes (or tumor promoting genes). there are several other genes that are often overepressed, which are separate from the ras pathway. furthermore, there are another class of genes called tumor suppressor genes, which are often inhibited or permanently lost from cancer cells. unfortunately, stopping the ras pathway will not stop cancer cells which are driven by these phenomena."
The kind of RAS activation that the Reovirus exploits is implicated in probably over 2/3's of all cancers. When you talk about metatastic cancer, the kind that kills, researchers from Yale have implicated RAS.
http://www.med.yale.edu/external/pubs/ym_sp04/fin
"research demonstrates that Ras also contributes to metastasis"
Throw in its synergistic and additive effects with chemo and radiation, and you've got a pretty potent therapy.
Yes I did try to get help writing the blurb and posting it to a wider audience. Its a story that deserves to be told. I've been holding this stock for quite a number of years now and am not selling it soon. Follow the links I've posted, there is a lot of third party independent research that validates this.
1. What is a virus?
A virus is a submicroscopic organism that can multiply only inside living host cells. It has a non-cellular structure lacking any intrinsic metabolism and usually comprising DNA or RNA molecules inside a protein coat. While the better known viruses are pathogenic (meaning they cause disease) many do not.
2. How do viruses behave?
Viruses need to infect living cells to multiply. They typically invade a cell, then take over the cell's manufacturing capabilities so that they may replicate. Replicated viral particles then invade surrounding cells.
3. What is the reovirus?
Reovirus is an acronym for Respiratory Enteric Orphan Virus. The reovirus is a naturally occurring virus to which most of us have been exposed in our lifetime. It is a non-pathogenic virus, meaning that it is not usually associated with any illness. Between 70 and 100 per cent of the population show signs of previous reovirus infection, which is usually confined to the respiratory or gastrointestinal systems in the body.
4. Where does the reovirus come from?
Reovirus is found naturally in shallow pools of water, lakes or streams or in the sewage system.
5. How were its cancer-killing properties discovered?
The reovirus was identified almost half a century ago, but was found to be a fairly benign virus. Because of its safety profile, it has been used for decades by scientists interested in studying how viruses infect human cells. Through the 1990s, graduate students and professors working at the University of Calgary discovered through a series of experiments that the reovirus appeared to have an ability to infect and kill many types of cancer cells, without affecting normal, healthy cells.
6. Why doesn't the reovirus infect normal cells?
It enters normal cells, but when this happens, an anti-viral response mechanism is turned on and the virus is quickly eliminated. Anyone injected with reovirus is usually able to clear it completely from the body in about two weeks.
7. Why does the reovirus kill cancer cells?
Scientific studies have demonstrated that approximately two-thirds of all human cancer cells have an activated Ras pathway, one of the most common set of mutations leading to cancer. An activated Ras pathway leads to a constant barrage of growth signals to the cell, causing uncontrolled growth. In cells with an activated Ras pathway, the anti-viral response appears to be turned off. When reovirus infects one of these cancer cells, it is able to replicate and eventually kill the cancer cell. Up to 5,000 progeny virus particles can then infect and kill surrounding cancer cells. Theoretically, the cycle of infection, replication and cell death will continue until there are no longer any Ras-activated cancer cells accessible.
8. How is reovirus administered to patients?
Oncolytics is pursuing a three-pronged approach to developing REOLYSIN®: localized administration using REOLYSIN® as a monotherapy; systemic administration using REOLYSIN® as a monotherapy; and, combination therapy using REOLYSIN® with radiation or chemotherapy.
9. Why isn't REOLYSIN® available to people yet?
Experimental drugs are not usually available to people outside clinical trials, except in rare cases. REOLYSIN® must be approved for sale by the regulatory agencies before it is made widely available to people.
10. Is REOLYSIN® available through programs such as Canada's Special Access Program?
The Company will not approve requests for treatment with REOLYSIN® through programs such as the SAP. Oncolytics treats only those patients who qualify for enrollment in its clinical trials.
11. How long does the clinical trial process take?
It varies, depending on the numbers of patients required for the trials and the kinds of results that are observed.
12. Why are your patient populations relatively small?
The trials that have been completed, and those that are underway, are designed to show that REOLYSIN® is safe and
The body's immune response is a big question that this Marsden intravenous trial is trying to answer. It seems like the reovirus can overcome the immune response long enough to do its work. The higher doses they plan to administer will also help. Immunosuppressants can ultimately be administered too. In animal models, this approach has shown increased effectiveness too.
Take a look at the third party research links that has confirmed the company pr you mention. This is real, its safe, and it is easy to produce. Cheers.
No, the ReoVirus has not been genetically altered. Do some more reading.
Yeah I got some feedback from yahoo and stockhouse message boards before I submitted the summary to slashdot. I've done a lot of DD on this and am not selling my shares for at least a couple of years. Six bucks is way too cheap for an effective treatment for Cancer, even in American dollars ...
They are planning systemic studies which means that it will be injected directly into your veins and go to where your blood goes. Only place that won't be treatable is brain cancer where direct injection will be necessary.
Its actually NOT an engineered virus. You are correct in saying that Adenovirus is genitically engineered as are most other virus oncology programs but the Reovirus is not genetically altered. It is quite significant in terms of being able to produce large quantities of this and also in terms of safety, the Reovirus is stable and won't mutate into something dangerous. You need to do more research. The SciAm article mentioned reovirus but it was the only one of those five treatments that wasn't engineered.
Lead Product REOLYSIN - A potential cancer therapeutic based on the naturally occurring reovirus. REO is an acronym for respiratory enteric orphan. Orphan due to the fact that there is no known disease caused by the reovirus. 70-100% of all adult populations have been infected with the reovirus without knowing it. The oncolytic properties of the reovirus were discovered in 1998 by Dr. Patrick Lee at the University of Calgary. Preclinical Glioblastoma: - glioma tumours U251N and U87lacZ implanted intracerebrally in mice - median survival of untreated mice, 42 and 48 days - 67% and 82% of treated animals still alive at conclusion of experiment at day 90 - complete tumour regression found in 20 of 23 of animals treated with live virus - also tested on established glioma cell lines and surgical specimens - widespread cell killing seen in 19 of 24 cell lines - all primary surgical glioma specimens (9 of 9) were infected and killed - human glioma tumour cells killed within 48 hour period (both cell lines and ex vivo glioma specimens) - dramatic survival benefits for nude mice following intracerebral inoculation - caused tumour regression in the presence of pre-existing anti-reovirus antibodies in immunocompetent Fischer rats - killed tumour remote from the site of administration in immunocompetent host - proceeding to clinical trial in patients with malignant gliomas Medulloblastoma: - majority of cell lines (7 of 11) were susceptible to reovirus oncolysis - in all MB cell lines tested, Ras activity was shown to correlate with susceptibility to reovirus infection - median survival of live virus-treated mice was 160 days, compared to 70 days control - these data suggest that reovirus may be a novel and potentially effective therapeutic against human medulloblastoma Breast: - widespread cell killing was seen in all five established breast cancer cell lines and in one surgical specimen - no cell killing observed in two cell lines established from normal breast tissue - in mammary fat pad of SCID/NOD mice, a single injection of reovirus caused a continuous regression of the tumour during a thirty-day observation period - independent tumours established in both flanks of the mice, a single injection of the reovirus into only one tumour resulted in complete regression of both the injected and non-injected tumours over thirty-two days Colon: - efficiently infected 5/5 human colon cancer cell lines (Caco-2, DLD-1, HCT-116, HT-29, and SW48) - did not infect normal colon cell line (CCD-18Co) - in mice model with tumour implanted in hind flank, both intratumoural and i.v. administration of reovirus resulted in significant regression Ovarian: - efficiently infected 4/4 human ovarian cancer cell lines (MDAH2774, PA-1, SKOV3, and SW626) - did not infect normal ovarian cell line (NOV-31) - in mice model with tumour implanted in hind flank, both intratumoural and i.v. administration of reovirus resulted in significant regression - significantly greater survival benefits for reovirus treated mice - reovirus infected ex vivo primary human ovarian surgical samples Non-Hodgkin's Lymphomas: - cell lines sensitive to reovirus: Raji, NC-37, UJ937 and CA46 - cell lines unaffected by reovirus: Daudi, ST486, Ramos, and A20 - ex vivo samples responded in similar ratio - reovirus caused significant regression of in vivo Raji tumour - reovirus may be effectivce against some types of human NHL Prostate: - prostate cell lines (PC-3, Ln-CaP, DU-145) were infected with reovirus - cells were harvested at 0, 24, 48, 72, 96 and 168h post infection - virus treatment caused significant disruption of cells as early as 24h - the observed cytopathic/apoptotic effects of reovirus were not evident in controls Pancreatic: - from Matt Coffey's thesis, pancreatic cell lines Capan-1, MIAPaCa-2, PANC-1, AsPC-1, and Hs766T were infectible while BxPC-3 was not (it is known to have wild type Ras) the others have mutations in codon 12 so are expected to be infectible Lewis lung: - in a Lewis lung carcinoma mouse model, they [Dr. Lee, et al] demonstrated that IV treatm
No, this is a naturally occuring virus. Its not one that is genetically engineered. The advantages are huge - easier to mass produce and much safer, it won't revert into something harmful